Innovative Technology Adoption ANEUVO's development of the ExaStim® non-invasive neuromodulation system, which has received CE Mark approval and FDA Breakthrough Device Designation, positions it as a cutting-edge provider in medical device technology, creating opportunities to collaborate or supply compatible components and integrated solutions.

Strong Market Validation Winning the 22nd National Innovation Award and participating in prominent industry events like RehaCare 2025 and ISCoS 2025 demonstrates recognition of ANEUVO's innovative approaches, aiding in establishing credibility and opening doors for partnerships with healthcare providers and research institutions.

Growing Funding and Support Recent Series C funding of $22 million highlights investor confidence and financial stability, enabling the company to expand its commercialization efforts, accelerate product development, and explore new markets, especially in Europe where ExaStim is CE marked.

Regulatory and Geographic Focus With ExaStim® approved in Europe and limited to investigational use in the US, there is a clear opportunity to support ANEUVO in regulatory strategy, clinical trials, and eventual commercialization efforts across different regions, especially targeting healthcare systems focused on spinal injury treatments.

Emerging Market Demand The company's focus on non-invasive therapies for spinal cord injury aligns with a growing global demand for less invasive, innovative medical solutions, presenting sales opportunities within rehabilitation centers, research hospitals, and government health programs seeking advanced treatment modalities.